CD36 and metabolic dysfunction-associated steatohepatitis: These findings suggest that palmitoylation modification is able to regulate the subcellular localization and biological functions of CD36, and that targeting hepatic CD36 palmitoylation modification may be a novel strategy for the treatment of MASH.